Related Experiment Video

Updated: Aug 24, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

[Cardiometabolic therapy of ischemic heart disease]

A P Vasil'ev, N N Strel'tsova, Iu N Senatorov

    Klinicheskaia Meditsina
    |May 29, 2004
    PubMed

    Insights

    This study found that adding membran-protective drugs (MPD) to standard treatment improved exercise tolerance in ischemic heart disease patients. MPD therapy reduced lipid peroxidation and stabilized cell membranes for better cardiac performance.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Biochemistry

    Background:

    • Ischemic heart disease with effort angina impacts cardiac performance and exercise tolerance.
    • Current treatments focus on antianginal drugs, but further improvements are sought.

    Purpose of the Study:

    • To evaluate the efficacy of adding membran-protective drugs (MPD) to antianginal therapy.
    • To assess the impact of MPD on lipid peroxidation, cell membrane structure, and exercise tolerance in patients with ischemic heart disease.

    Main Methods:

    • A study involving 59 patients with ischemic heart disease and effort angina (functional classes II-IV).
    • Patients were divided into two groups: one received antianginal drugs plus MPD, the other received antianginal drugs alone.
    • Measurements included blood lipid peroxidation products, erythrocyte membrane lipid structure, and exercise tolerance before and after treatment.

    Main Results:

    • The group receiving MPD showed reduced lipid peroxidation activity.
    • MPD therapy led to stabilization of the erythrocyte cell membrane structure.
    • Patients treated with MPD exhibited greater exercise tolerance attributed to improved cardiac performance.

    Conclusions:

    • Membran-protective drugs (MPD) offer a beneficial addition to antianginal therapy for ischemic heart disease.
    • MPD therapy positively influences biochemical markers and functional capacity in these patients.
    • The findings suggest MPD can enhance cardiac performance and exercise tolerance.

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...